BioCentury
ARTICLE | Clinical News

miRagen reports systemic microRNA therapy data in CTCL

October 13, 2017 9:25 PM UTC

miRagen Therapeutics Inc. (NASDAQ:MGEN) reported interim data from the second part of an ongoing Phase I trial of MRG-106 in patients with mycosis fungoides-type cutaneous T cell lymphoma (CTCL). Among 23 patients receiving the systemically administered microRNA therapy, all but one showed improvement in total skin disease.

miRagen President and CEO William Marshall told BioCentury the trial's results are the first for a systemic anti-microRNA therapy in oncology...

BCIQ Company Profiles

Viridian Therapeutics Inc.

BCIQ Target Profiles

MicroRNA-155 (miR-155)